USANA Health Sciences (NYSE:USNA) Updates FY 2026 Earnings Guidance

USANA Health Sciences (NYSE:USNA) issued an update on its FY 2026 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 0.760-0.760 for the period, compared to the consensus earnings per share estimate of 2.120. The company issued revenue guidance of $910.0 million-$910.0 million, compared to the consensus revenue estimate of $945.1 million.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Weiss Ratings reissued a “sell (d)” rating on shares of USANA Health Sciences in a report on Wednesday, June 24th. Zacks Research downgraded USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 22nd. Finally, Wall Street Zen raised USANA Health Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, June 20th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Reduce”.

USANA Health Sciences Trading Up 0.2%

Shares of USANA Health Sciences stock traded up $0.05 on Tuesday, reaching $22.89. 123,607 shares of the stock were exchanged, compared to its average volume of 119,795. The firm has a market capitalization of $422.53 million, a PE ratio of 48.70, a PEG ratio of 0.87 and a beta of 0.73. USANA Health Sciences has a 1-year low of $16.60 and a 1-year high of $32.32. The business has a fifty day moving average price of $20.53 and a two-hundred day moving average price of $19.77.

USANA Health Sciences (NYSE:USNA) last released its earnings results on Tuesday, August 4th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.43 by ($0.50). The business had revenue of $223.27 million for the quarter, compared to analyst estimates of $235.00 million. USANA Health Sciences had a return on equity of 6.21% and a net margin of 0.96%.USANA Health Sciences has set its FY 2026 guidance at 0.760-0.760 EPS. Research analysts expect that USANA Health Sciences will post 2.12 EPS for the current year.

Insiders Place Their Bets

In related news, Director John Turman Fleming sold 2,450 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $17.93, for a total transaction of $43,928.50. Following the transaction, the director owned 4,230 shares of the company’s stock, valued at $75,843.90. This represents a 36.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Joshua Foukas sold 3,791 shares of the stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $19.82, for a total value of $75,137.62. The SEC filing for this sale provides additional information. Insiders have sold 17,660 shares of company stock valued at $336,579 in the last three months. 0.82% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On USANA Health Sciences

Large investors have recently made changes to their positions in the stock. Russell Investments Group Ltd. increased its holdings in USANA Health Sciences by 4.6% during the 4th quarter. Russell Investments Group Ltd. now owns 12,431 shares of the company’s stock valued at $244,000 after acquiring an additional 542 shares in the last quarter. Quantbot Technologies LP raised its position in USANA Health Sciences by 19.5% during the second quarter. Quantbot Technologies LP now owns 3,957 shares of the company’s stock worth $121,000 after acquiring an additional 646 shares during the last quarter. Intech Investment Management LLC lifted its holdings in shares of USANA Health Sciences by 13.5% in the third quarter. Intech Investment Management LLC now owns 7,722 shares of the company’s stock valued at $213,000 after purchasing an additional 918 shares in the last quarter. National Bank of Canada FI lifted its holdings in shares of USANA Health Sciences by 166.6% in the third quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock valued at $53,000 after purchasing an additional 1,201 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of USANA Health Sciences by 52.9% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,834 shares of the company’s stock valued at $106,000 after purchasing an additional 1,327 shares during the last quarter. Hedge funds and other institutional investors own 54.25% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.